MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - pharmaceuticals
- AMAR REMEDIES - GILLETTE INDIA
AMAR REMEDIES vs GILLETTE INDIA - Comparison Results
Current Valuations
| AMAR REMEDIES | GILLETTE INDIA | AMAR REMEDIES/ GILLETTE INDIA |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | -0.5 | 66.9 | - | View Chart |
| P/BV | x | 0.1 | 25.7 | 0.2% | View Chart |
| Dividend Yield | % | 0.0 | 0.4 | - |
Financials
 AMAR REMEDIES  GILLETTE INDIA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| AMAR REMEDIES Jun-12 |
GILLETTE INDIA Jun-18 |
AMAR REMEDIES/ GILLETTE INDIA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 164 | 7,197 | 2.3% | |
| Low | Rs | 86 | 5,002 | 1.7% | |
| Sales per share (Unadj.) | Rs | 261.6 | 514.5 | 50.8% | |
| Earnings per share (Unadj.) | Rs | 17.4 | 70.3 | 24.7% | |
| Cash flow per share (Unadj.) | Rs | 22.3 | 83.3 | 26.8% | |
| Dividends per share (Unadj.) | Rs | 0 | 23.00 | 0.0% | |
| Dividend yield (eoy) | % | 0 | 0.4 | 0.0% | |
| Book value per share (Unadj.) | Rs | 100.7 | 213.0 | 47.3% | |
| Shares outstanding (eoy) | m | 26.16 | 32.59 | 80.3% | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 0.5 | 11.9 | 4.0% | |
| Avg P/E ratio | x | 7.2 | 86.8 | 8.3% | |
| P/CF ratio (eoy) | x | 5.6 | 73.3 | 7.7% | |
| Price / Book Value ratio | x | 1.2 | 28.6 | 4.3% | |
| Dividend payout | % | 0 | 32.7 | 0.0% | |
| Avg Mkt Cap | Rs m | 3,270 | 198,775 | 1.6% | |
| No. of employees | `000 | NA | 0.6 | 0.0% | |
| Total wages/salary | Rs m | 163 | 1,179 | 13.8% | |
| Avg. sales/employee | Rs Th | NM | 27,002.4 | - | |
| Avg. wages/employee | Rs Th | NM | 1,898.7 | - | |
| Avg. net profit/employee | Rs Th | NM | 3,688.4 | - | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 6,844 | 16,769 | 40.8% | |
| Other income | Rs m | 21 | 128 | 16.5% | |
| Total revenues | Rs m | 6,865 | 16,896 | 40.6% | |
| Gross profit | Rs m | 1,131 | 3,816 | 29.6% | |
| Depreciation | Rs m | 128 | 423 | 30.3% | |
| Interest | Rs m | 398 | 75 | 533.5% | |
| Profit before tax | Rs m | 626 | 3,446 | 18.2% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | -50 | 0 | - | |
| Tax | Rs m | 121 | 1,156 | 10.5% | |
| Profit after tax | Rs m | 455 | 2,291 | 19.9% | |
| Gross profit margin | % | 16.5 | 22.8 | 72.6% | |
| Effective tax rate | % | 19.3 | 33.5 | 57.6% | |
| Net profit margin | % | 6.6 | 13.7 | 48.7% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 4,904 | 6,742 | 72.7% | |
| Current liabilities | Rs m | 3,581 | 4,794 | 74.7% | |
| Net working cap to sales | % | 19.3 | 11.6 | 166.4% | |
| Current ratio | x | 1.4 | 1.4 | 97.4% | |
| Inventory Days | Days | 124 | 44 | 285.2% | |
| Debtors Days | Days | 100 | 38 | 261.4% | |
| Net fixed assets | Rs m | 1,689 | 3,048 | 55.4% | |
| Share capital | Rs m | 262 | 326 | 80.4% | |
| "Free" reserves | Rs m | 2,358 | 6,616 | 35.6% | |
| Net worth | Rs m | 2,635 | 6,942 | 38.0% | |
| Long term debt | Rs m | 507 | 0 | - | |
| Total assets | Rs m | 6,862 | 12,090 | 56.8% | |
| Interest coverage | x | 2.6 | 47.2 | 5.5% | |
| Debt to equity ratio | x | 0.2 | 0 | - | |
| Sales to assets ratio | x | 1.0 | 1.4 | 71.9% | |
| Return on assets | % | 12.4 | 19.6 | 63.5% | |
| Return on equity | % | 17.3 | 33.0 | 52.3% | |
| Return on capital | % | 31.0 | 50.7 | 61.1% | |
| Exports to sales | % | 4.0 | 0 | - | |
| Imports to sales | % | 0 | 0 | - | |
| Exports (fob) | Rs m | 273 | NA | - | |
| Imports (cif) | Rs m | NA | NA | - | |
| Fx inflow | Rs m | 273 | 2,782 | 9.8% | |
| Fx outflow | Rs m | 2 | 5,079 | 0.0% | |
| Net fx | Rs m | 271 | -2,296 | -11.8% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | -313 | 2,371 | -13.2% | |
| From Investments | Rs m | -489 | -768 | 63.6% | |
| From Financial Activity | Rs m | 769 | -392 | -195.9% | |
| Net Cashflow | Rs m | -33 | 1,211 | -2.7% | |
Share Holding
| Indian Promoters | % | 25.5 | 34.9 | 73.1% | |
| Foreign collaborators | % | 0.0 | 40.1 | - | |
| Indian inst/Mut Fund | % | 9.2 | 0.9 | 1,022.2% | |
| FIIs | % | 0.0 | 7.8 | - | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 65.3 | 16.3 | 400.6% | |
| Shareholders | 13,061 | 18,623 | 70.1% | ||
| Pledged promoter(s) holding | % | 99.7 | 0.0 | - |
Compare AMAR REMEDIES With: RELAXO FOOTWEARS K.S.OILS LTD COLGATE ARCHIES LTD GODREJ INDUSTRIES
Compare AMAR REMEDIES With: P&G (US) UNILEVER PLC. (UK) HYPERMARCAS (Brazil)
Today's Market
Relief Rally for Indian Indices, PSB Merger Scheme, Upcoming IPOs, and Top Cues in Focus Today(Pre-Open)
Indian share markets ended on a strong note yesterday, tracking global cues. Benchmark indices extended gains as the session progressed, as relatively better factory output data.
Related Views on News
GILLETTE INDIA Announces Quarterly Results (3QFY20); Net Profit Up 31.6% (Quarterly Result Update)
Feb 14, 2020 | Updated on Feb 14, 2020For the quarter ended December 2019, GILLETTE INDIA has posted a net profit of Rs 711 m (up 31.6% YoY). Sales on the other hand came in at Rs 5 bn (down 3.4% YoY). Read on for a complete analysis of GILLETTE INDIA's quarterly results.
GILLETTE INDIA Announces Quarterly Results (2QFY20); Net Profit Down 5.5% (Quarterly Result Update)
Nov 11, 2019 | Updated on Nov 11, 2019For the quarter ended September 2019, GILLETTE INDIA has posted a net profit of Rs 618 m (down 5.5% YoY). Sales on the other hand came in at Rs 5 bn (up 1.2% YoY). Read on for a complete analysis of GILLETTE INDIA's quarterly results.
GILLETTE INDIA Announces Quarterly Results (4QFY19); Net Profit Up 23.1% (Quarterly Result Update)
May 9, 2019 | Updated on May 9, 2019For the quarter ended March 2019, GILLETTE INDIA has posted a net profit of Rs 878 m (up 23.1% YoY). Sales on the other hand came in at Rs 5 bn (up 3.1% YoY). Read on for a complete analysis of GILLETTE INDIA's quarterly results.
GILLETTE INDIA Announces Quarterly Results (3QFY19); Net Profit Down 8.1% (Quarterly Result Update)
Feb 12, 2019 | Updated on Feb 12, 2019For the quarter ended December 2018, GILLETTE INDIA has posted a net profit of Rs 540 m (down 8.1% YoY). Sales on the other hand came in at Rs 5 bn (up 16.7% YoY). Read on for a complete analysis of GILLETTE INDIA's quarterly results.
GILLETTE INDIA Announces Quarterly Results (2QFY19); Net Profit Up 1.6% (Quarterly Result Update)
Nov 5, 2018 | Updated on Nov 5, 2018For the quarter ended September 2018, GILLETTE INDIA has posted a net profit of Rs 654 m (up 1.6% YoY). Sales on the other hand came in at Rs 5 bn (up 11.9% YoY). Read on for a complete analysis of GILLETTE INDIA's quarterly results.
More Views on NewsMost Popular
If I Were to Recommend One Stock Amid Coronavirus Outbreak, This Would be It.(Profit Hunter)
Mar 19, 2020Coronavirus outbreak has made no impact on the long term prospects of my favourite smallcap. What it has indeed done is brought the company below my buy price, making it even more attractive investment at current price.
Why India Will Be the Biggest Winner in a Post-Coronavirus World(The 5 Minute Wrapup)
Mar 19, 2020The way businesses operate will change in a major way post the coronavirus impact. Here's why India stands to benefit from this change...
A Big Trading Opportunity is Coming Your Way Soon(Fast Profits Daily)
Mar 25, 2020I see a big opportunity to make fast profits on the horizon.
Sorry Warren Buffett, I'm Following This Man Instead of You in 2020(The 5 Minute Wrapup)
Mar 30, 2020This man warned of an impending market correction while everyone else was celebrating the renewed optimism in early 2020...
Coronavirus Sell-off Is a Perfect Time to 'Lockdown' this 'Crorepati' Stock(Profit Hunter)
Mar 24, 2020Coronavirus crisis and panic selling has brought this quality smallcap to multiyear lows, making it a great bargain.
MoreOUR TOP 5 IDEAS
- How to Trade the Coronavirus Crash - Download this FREE Report Now
- How to Profit Even During These Times of Crisis: Vijay Bhambwani Reveals his Strategy...
- The Best Stocks For 2020 - How to Spot Multibagger Ideas. FREE Sign up!
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- Find Out Our Top 7 Bluechips for 2020 Virtually FREE. Click Here Now!
AMAR REMEDIES SHARE PRICE
Dec 11, 2013 (Close)
TRACK AMAR REMEDIES
- Track your investment in AMAR REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON AMAR REMEDIES
AMAR REMEDIES 8-QTR ANALYSIS
COMPARE AMAR REMEDIES WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.